Clinical Trial Update: The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus [Phase 4]

View source ↗

Summary

A Phase 4 study comparing tiotropium/olodaterol (Stiolto) inhaled via Respimat vs fluticasone/salmeterol (Advair) via Diskus in COPD; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Advair (fluticasone propionate/salmeterol)
• Stiolto (tiotropium/olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2020-04-16